Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.08 per share when it actually produced a loss of $0.10, delivering a surprise of -25%.Over the las ...